Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.2.873

Preoperative Levels of Matrix Metalloproteinase-7 and -9 and Tissue Inhibitor of Matrix Metalloproteinase-1 Relation to Pathologic Parameters in Bladder Carcinoma Patients  

Gunes, Mustafa (Department of Urology, Yuzuncu Yil University Medical Faculty)
Kemik, Ahu Serap (Department of Biochemistry, Cerrahpasa Medical Faculty, University of Istanbul)
Pirincci, Necip (Department of Urology, Yuzuncu Yil University Medical Faculty)
Gecit, Ilhan (Department of Urology, Yuzuncu Yil University Medical Faculty)
Taken, Kerem (Urology Clinic of Van State Hospital)
Yuksel, Mehmet Bilgehan (Department of Urology, Celal Bayar University Medical Faculty)
Kaba, Mehmet (Urology Clinic of Van State Hospital)
Eryilmaz, Recep (Department of Urology, Yuzuncu Yil University Medical Faculty)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.2, 2013 , pp. 873-876 More about this Journal
Abstract
Our aim was to test the hypothesis that preoperative serum levels of matrix metalloproteinase-7 (MMP-7) and -9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) levels correlate with pathological features. Serum levels of MMP-7, and MMP-9 and TIMP-1 were determined in 90 bladder cancer patients and 40 healthy controls using an enzyme linked immunosorbent assay. Preoperative serum MMP-7 and MMP-9 levels were significantly higher in cancer patients than control groups (p<0.001). In contast, serum TIMP-1 levels were lower (p<0.001). Alteration in MMP-7, and MMP-9, and TIMP-1 production may contribute to tumor angiogenesis and be associated with clinic-pathological features.
Keywords
MMP-7; MMP-9; TIMP-1; bladder cancer; pathological parameters;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Anton-Culver H, Lee-Feldstein A, Taylor TH (1992). Occupation and bladder cancer risk. Am J Epidemiol, 136, 89-94.
2 Andersen JB, Aaboe M, Borden EC, et al (2006). Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer, 94, 1465-71.   DOI   ScienceOn
3 Cheng HC, Yang HB, Chang WL, et al (2012). Expressions of MMPs and TIMP-1 in gastric ulcers may differentiate H. pylori-infected from NSAID-related ulcers. Sci World J, 10, 539316.
4 Cornelius LA, Nehring LC, Harding E, et al (1998). Matrix metalloporteinases generate angiostatin: effect of neovascularization. J Immunol, 161, 6845-52.
5 Durkan GC, Nutt JE, Marsh C, et al (2003). Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer. Clin Cancer Res, 9, 2576-82.
6 Egeblad M, Werb Z (2009). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2, 161-74.
7 Guan KP, Hou SK, Yan Z, Ye HY (2003). Serum levels of endostatin and MMP-9 associated with high-stage and grade primary transitional cell carcinoma of the bladder cancer. Urology, 61, 719-23.   DOI   ScienceOn
8 Hashimoto K, Kihira Y, Matuo Y, Usui T (1998). Expression MMP-7 and TIMP-1 in human prostate. J Urol, 160, 1872-6.   DOI   ScienceOn
9 Hurst NG, Stocken DD, Wilson S, et al (2007). Elevated serum MMP-9 concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer, 97, 971-77.   DOI   ScienceOn
10 Hayakawa T, Yamashita K, Tanzawa K, et al (1992). Growth-promoting activity of tissue inhibitor of matrix metalloproteinase-1 for a wide range a cells. A possible new growth factor in serum. FEBS Lett. 298, 29-32.   DOI   ScienceOn
11 Johansen JL, Cohen SM (1997) Epidemiology and etiology of bladder cancer. Semin Surg Oncol, 13, 291-8.   DOI   ScienceOn
12 Kanayama H (2001) Matrix metalloproteinases and bladder cancer. J Med Invest, 48, 31-43.
13 Lipton A, Ali S, Demers L, et al (2007). Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 109, 1933-8.   DOI   ScienceOn
14 Koss LG, Deitch D, Ramathan R, Sherman AB (1985) Diagnostic value of cytology of voided urine. Acta Cytol, 29, 810-6.
15 Laleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR (2002). Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases. J Cell Sci, 115, 3427-8.
16 Leelawat K, Narong S, Wannaprasert J, Ratanashu T (2010). Prospective study of MMP-7 levels in the cholangiocarcainoma. World J Gastro, 16, 4697-703.   DOI
17 Li G, Fridman R, Kim HR (1999). TIMP-1 inhibits apopotosis of human breast epithelial cells. Cancer Res, 59, 6267-75.
18 Martinez-Fernandez A, Garcia-Albeniz X, Pineda E, et al (2009). Serum matrilysin levels predict outcome curatively resected colorectal cancer patients. Ann Surg Oncol, 16, 1412-20.   DOI
19 McQuibban GA, Gong JH, Wong JB, et al (2000). Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science, 289, 1202-06.   DOI   ScienceOn
20 McQuibban GA, Butler GS, Gong JH, et al (2001). Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem, 276, 43503-8.   DOI   ScienceOn
21 Murray D, Morrin M, Mc Donnel S (2004) Increased invasion and expression of MMP-9 in human colorectal lines by a CD44-dependent mechanism. Anticancer Res, 24, 489-94.
22 Naruo S, Kanayama H, Takigawa H (1994) Serum levels of TIMP-1 in bladder cancer patients. Int J Urol, 1, 228-31   DOI   ScienceOn
23 Sheu BC, Hsu SM, Ho HN, et al (2001). A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res, 61, 237-42.
24 Park HD, Kang ES, Kim JW, et al (2012). Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Proteomics, 12, 3590-7.   DOI   ScienceOn
25 Ray JM, Stetler-Stevenson WG (1994) The role of matrix metalloproteinase and their inhibitors in tumor invasion, metastasis and angiogenesis. Eur Respir J, 7, 2062-72.
26 Sharma S, Ksheersagar P, Sharma P (2009) Diagnosis and treatment of bladder cancer. Am Family Physician, 80, 717-23.
27 Slaton JW, Millikan R, Inoue K, et al (2004). Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated cystectomy and chemotherapy. J Urol, 171, 570-4.   DOI   ScienceOn
28 Szarvas T, Jager T, Becker M, et al (2011). Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathol Oncol Res, 17, 325-32.   DOI   ScienceOn
29 Szarvas T, Becker M, vom Dorp F, et al (2010). MMP-7 as a marker of metastasis and predictor of poor urvival in bladder cancer. Cancer Sci, 101, 1300-8.l   DOI   ScienceOn
30 Szarvas T, Singer BB, Becker M, et al (2010). Urinary MMP-7 level is associated with the presence of metastasis in bladder cancer. BJU Int, 7, 1069-73.
31 Torii A, Kodera Y, Uesaka K, et al (1997). Plasma concentration of MMP-9 in gastric cancer. Br J Cancer, 84, 133-6.
32 Wallard MJ, Pennington CJ, Veerakumarasivam A, et al (2006). Comprehensive profiling and localization of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer, 94, 569-77.   DOI   ScienceOn
33 Yang B, Su K, Gao J, Rao Z (2012) Expression and prognostic value of matrix metalloproteinase-7 in colorectal cancer. Asian Pac J Cancer Prev, 13, 1049-52.   DOI   ScienceOn
34 Wu ZS, Wu Q, Yang JH, et al (2008). Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer, 122, 2050-6.   DOI   ScienceOn
35 Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM (2002). Identification of novel matrix metalloproteinase-7 cleavage sites in murine and human Fas ligand. Arch Biochem Biophys, 408, 155-61.   DOI   ScienceOn
36 Vasala K, Paakko P, Turpeenniemi-Hujanen T (2008). MMP-9 immunorecative protein in urinary bladder cancer: a marker of favorable prognosis. Anticancer Res, 28, 1757-67.
37 Yeh YC, Sheu BS, Cheng HC, et al (2010). Elevated serum MMP-3 and -7 in H. pylori-related gastric cancer can be markers biomarkers correlating with a poor survival. Dig Dis Sci, 55, 1649-57.   DOI
38 Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T (2000). Serum MMP-2, and -9 and TIMP-1, -2 in lung cancer-TIMP-1 as prognostic marker. Anticancer Res, 20, 1311-6.
39 Yukawa N, Yoshikawa T, Akaike M, et al (2007). Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology, 72, 205-8.   DOI   ScienceOn
40 Zhou JH, Zhang B, Kernstine KH, Zhong L (2011). Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastro, 17, 1373-8.   DOI   ScienceOn